Eliem Therapeutics (NASDAQ:ELYM) (NASDAQ: ELYM) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for serious central nervous system (CNS) disorders. The company’s lead program, ELYM-1, is a proprietary, novel enantiomer of pregabalin being evaluated for the treatment of premenstrual dysphoric disorder (PMDD). By leveraging a targeted approach to modulate neuronal activity, Eliem aims to address unmet medical needs in neuropsychiatric conditions with a high burden of disease and limited therapeutic options.
Founded in 2018 and headquartered in San Francisco, California, Eliem Therapeutics has built a robust pipeline centered on innovative small-molecule candidates designed to normalize dysregulated neurotransmission. In addition to PMDD, the company is exploring potential indications in related mood and anxiety disorders, positioning its platform to serve a broad patient population. Eliem’s research and development efforts are supported by a combination of internal discovery programs and strategic collaborations with academic and industry partners.
Since its initial public offering, Eliem has advanced ELYM-1 through Phase 2 clinical trials and is preparing for pivotal studies later this year. The company’s management team is led by Chief Executive Officer David Zaccard, whose background spans oncology and neuroscience drug development. The executive leadership is complemented by a seasoned board of directors and scientific advisory board, bringing expertise in regulatory affairs, clinical operations, and commercial strategy.
Eliem Therapeutics seeks to expand its presence both domestically and internationally, with clinical trial sites across North America and plans for future studies in Europe and Asia. As the company progresses toward regulatory milestones, it aims to establish itself as a leader in the CNS space by delivering differentiated, patient-focused therapies. Through disciplined development and strategic partnerships, Eliem is committed to transforming the standard of care for individuals affected by debilitating neuropsychiatric conditions.
